ImmunoPrecise Antibodies (OTCQB:IPATF) announces a research collaboration with Zymeworks (NYSE:ZYME) giving the Company access to Zymeworks’ Azymetric and EFECT platforms for the further development of its multiple antibody candidates to fight COVID-19.
Under the terms of the agreement, IPA will transform its previously tested and potent SARS-CoV-2 neutralizing antibodies into bispecific and multispecific antibodies using the Zymeworks’ platforms.
These sets of candidates will be thoroughly tested using SARS-CoV-2 spike protein provided by the National Research Council Canada, prior to pre-clinical manufacturing for animal studies.
https://seekingalpha.com/news/3614905-immunoprecise-teams-up-zymeworks-for-covidminus-19-antibody
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.